Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-lnduced emesis

Massimo Franchi, Nicoletta Donadello, Flavia Zanaboni, Anna Tusei, Elisabetta Scorbati

Research output: Contribution to journalArticlepeer-review

Abstract

Fifty-eight previously untreated patients with gynecological cancer, assigned to cisplatin-based chemotherapy (40–80 mg/m2), received the following antiemetic treatment: day 0, oral ondansetron 8 mg 3 times/day + intravenous dexamethasone 16 mg; days 1–7, oral ondansetron 8 mg twice/day. In cycle 1 complete or major control (0–2 emetic episodes) was achieved in 94.6% of the patients in the acute phase (day 0) and in 89.2% in the delayed phase (day 1-7). In the subgroup receiving cisplatin ≥ 75 mg/m2 the effect on acute and delayed emesis decreased significantly with subsequent courses. Reversible side effects were observed in 8.9% of the cases. Oral ondansetron was efficacious, well tolerated and is worth testing further in randomized trials with intravenous therapy.

Original languageEnglish
Pages (from-to)509-512
Number of pages4
JournalOncology
Volume52
Issue number6
DOIs
Publication statusPublished - 1995

Keywords

  • Acute and delayed emesis
  • Antiemetics
  • Ondansetron

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-lnduced emesis'. Together they form a unique fingerprint.

Cite this